Current Hematologic Malignancy Reports

, Volume 6, Issue 1, pp 58–66

Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?

  • Deborah A. Thomas
  • Susan O’Brien
  • Stefan Faderl
  • John T. ManningJr
  • Jorge Romaguera
  • Luis Fayad
  • Fredrick Hagemeister
  • Jeffrey Medeiros
  • Jorge Cortes
  • Hagop Kantarjian
Article

DOI: 10.1007/s11899-010-0076-4

Cite this article as:
Thomas, D.A., O’Brien, S., Faderl, S. et al. Curr Hematol Malig Rep (2011) 6: 58. doi:10.1007/s11899-010-0076-4

Abstract

Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, “B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL.” This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.

Keywords

Burkitt Burkitt-like Atypical Burkitt c-myc Non-Hodgkin lymphoma DLBCL WHO classification Therapy 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Deborah A. Thomas
    • 1
    • 4
  • Susan O’Brien
    • 1
  • Stefan Faderl
    • 1
  • John T. ManningJr
    • 2
  • Jorge Romaguera
    • 3
  • Luis Fayad
    • 3
  • Fredrick Hagemeister
    • 3
  • Jeffrey Medeiros
    • 2
  • Jorge Cortes
    • 1
  • Hagop Kantarjian
    • 1
  1. 1.Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of LymphomaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations